<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106508</url>
  </required_header>
  <id_info>
    <org_study_id>CLEQ506X2101</org_study_id>
    <secondary_id>2009-017969-30</secondary_id>
    <nct_id>NCT01106508</nct_id>
  </id_info>
  <brief_title>A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This first-in-human dose-escalation study is to characterize the safety, tolerability,
      pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in
      patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose and characterize the dose limiting toxicities of LEQ506</measure>
    <time_frame>21 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the safety and tolerability of LEQ506 treatment</measure>
    <time_frame>21 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of LEQ506</measure>
    <time_frame>21 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacodynamic effects of LEQ506 in skin and tumor samples</measure>
    <time_frame>21 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Recurrent or Refractory Medulloblastoma</condition>
  <condition>Locally Advanced or Metastatic Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>LEQ506</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEQ506</intervention_name>
    <arm_group_label>LEQ506</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma
             or locally advanced or metastatic basal cell carcinoma)

          -  Protocol defined laboratory parameters

          -  Performance status ≤ 2

          -  Patients must have fully recovered from the prior effects of major surgery and from
             any acute toxicities of prior chemotherapy/radiotherapy

        Exclusion Criteria:

          -  History of central nervous system tumors of symptomatic brain metastases (excludes
             medulloblastoma patients)

          -  Impairment of gastrointestinal function or unresolved nausea, vomiting or diarrhea

          -  Impairment of cardiac function or significant cardiac disease

          -  Pregnant or lactating women

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA LeConte Location</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>recurrent or refractory medulloblastoma</keyword>
  <keyword>locally advanced or metastatic basal cell carcinoma</keyword>
  <keyword>hedgehog pathway inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

